PT - JOURNAL ARTICLE ED - , TI - Kyleena – another levonorgestrel IUS AID - 10.1136/dtb.2018.2.0587 DP - 2018 Feb 01 TA - Drug and Therapeutics Bulletin PG - 18--20 VI - 56 IP - 2 4099 - http://dtb.bmj.com/content/56/2/18.short 4100 - http://dtb.bmj.com/content/56/2/18.full SO - Drug Ther Bull2018 Feb 01; 56 AB - A levonorgestrel (LNG) intrauterine system (IUS) known as Kyleena (Bayer PLC) received marketing authorisation from the European Medicines Agency in 2016.1 The device contains 19.5mg LNG and is licensed for contraception for up to 5 years. This is the fourth LNG IUS product to be licensed for use in the UK. The company states that Kyleena offers advantages over Mirena and Jaydess LNG IUS devices.2 Here we consider the evidence for Kyleena.